TY - JOUR
T1 - Anti-angiogenic perfluorocarbon nanoparticles for diagnosis and treatment of atherosclerosis
AU - Caruthers, Shelton D.
AU - Cyrus, Tillmann
AU - Winter, Patrick M.
AU - Wickline, Samuel A.
AU - Lanza, Gregory M.
PY - 2009/12/1
Y1 - 2009/12/1
N2 - Complementary developments in nanotechnology, genomics, proteomics, molecular biology and imaging offer the potential for early, accurate diagnosis. Molecularly-targeted diagnostic imaging agents will allow noninvasive phenotypic characterization of pathologies and, therefore, tailored treatment close to the onset. For atherosclerosis, this includes anti-angiogenic therapy with specificallytargeted drug delivery systems to arrest the development of plaques before they impinge upon the lumen. Additionally, monitoring the application and effects of this targeted therapy in a serial fashion will be important. This review covers the specific application of αvβ3-targeted anti-angiogenic perfluorocarbon nanoparticles in (1) the detection ofmolecular markers for atherosclerosis, (2) the immediate verification of drug delivery with image-based prediction of therapy outcomes, and (3) the serial, noninvasive observation of therapeutic efficacy.
AB - Complementary developments in nanotechnology, genomics, proteomics, molecular biology and imaging offer the potential for early, accurate diagnosis. Molecularly-targeted diagnostic imaging agents will allow noninvasive phenotypic characterization of pathologies and, therefore, tailored treatment close to the onset. For atherosclerosis, this includes anti-angiogenic therapy with specificallytargeted drug delivery systems to arrest the development of plaques before they impinge upon the lumen. Additionally, monitoring the application and effects of this targeted therapy in a serial fashion will be important. This review covers the specific application of αvβ3-targeted anti-angiogenic perfluorocarbon nanoparticles in (1) the detection ofmolecular markers for atherosclerosis, (2) the immediate verification of drug delivery with image-based prediction of therapy outcomes, and (3) the serial, noninvasive observation of therapeutic efficacy.
UR - http://www.scopus.com/inward/record.url?scp=77949331624&partnerID=8YFLogxK
U2 - 10.1002/wnan.9
DO - 10.1002/wnan.9
M3 - Article
C2 - 20049799
AN - SCOPUS:77949331624
SN - 1939-5116
VL - 1
SP - 311
EP - 323
JO - Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
JF - Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
IS - 3
ER -